Literature DB >> 29498795

Antibiotic resistance evolution of Pseudomonas aeruginosa in cystic fibrosis patients (2010-2013).

Francesca Lucca1, Margherita Guarnieri1, Mirco Ros2, Giovanna Muffato3, Roberto Rigoli3, Liviana Da Dalt1.   

Abstract

INTRODUCTION: Pseudomonas aeruginosa is the predominant pathogen responsible of chronic colonization of the airways in cystic fibrosis (CF) patients. There are few European data about antibiotic susceptibility evolution of P aeruginosa in CF patients.
OBJECTIVES: The aim of this study is to evaluate the evolution of antibiotic resistance in the period 2010-2013 in CF patients chronically colonized by P aeruginosa and to highlight the characteristics of this evolution in patients younger than 20 years.
METHODS: Clinical and microbiological data were extracted from two electronic databases and analyzed. Antibiotic resistance was defined according to European Committee of Antimicrobial Susceptibility Testing for levofloxacin, ciprofloxacin, meropenem, amikacin and ceftazidime. The between-group comparison was drawn with the Chi-square test for proportions, with the T-test for unpaired samples for normally distributed data and with Mann-Whitney test for non-normally distributed data. Significancy was defined by P < .05.
RESULTS: Fifty-seven CF patients, including thirteen subjects aged less than 20 years, were enrolled. P.. aeruginosa antibiotic sensitivity decreased significantly for fluoroquinolones, mainly in patients aged <20 years, while it increased for amikacin and colistin. The analysis of minimum inhibitory concentration confirmed these trends. In pediatric patients treated with more than three antibiotic cycles per year, greater resistance was found, except for amikacin and colistin.
CONCLUSION: An evolution in P aeruginosa antibiotic resistances is observed in the 4-year period studied. Responsible and informed use of antibiotics is mandatory in CF.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  cystic fibrosis; pediatrics; pulmonary infection; treatment

Mesh:

Substances:

Year:  2018        PMID: 29498795     DOI: 10.1111/crj.12787

Source DB:  PubMed          Journal:  Clin Respir J        ISSN: 1752-6981            Impact factor:   2.570


  6 in total

Review 1.  Virulence attenuating combination therapy: a potential multi-target synergy approach to treat Pseudomonas aeruginosa infections in cystic fibrosis patients.

Authors:  Elana Shaw; William M Wuest
Journal:  RSC Med Chem       Date:  2020-02-19

2.  Synergy of nebulized phage PEV20 and ciprofloxacin combination against Pseudomonas aeruginosa.

Authors:  Yu Lin; Rachel Yoon Kyung Chang; Warwick J Britton; Sandra Morales; Elizabeth Kutter; Hak-Kim Chan
Journal:  Int J Pharm       Date:  2018-09-14       Impact factor: 5.875

Review 3.  Approaches to Targeting Bacterial Biofilms in Cystic Fibrosis Airways.

Authors:  Isaac Martin; Valerie Waters; Hartmut Grasemann
Journal:  Int J Mol Sci       Date:  2021-02-22       Impact factor: 5.923

4.  Pharmacokinetics of Meropenem in People with Cystic Fibrosis-A Proof of Concept Clinical Trial.

Authors:  Jan C Kamp; Jan Fuge; Felix C Ringshausen; Denis Grote-Koska; Korbinian Brand; Lukas Graalmann; Ralf-Peter Vonberg; Tobias Welte; Jessica Rademacher
Journal:  Antibiotics (Basel)       Date:  2021-03-11

5.  Variability in Bacteriophage and Antibiotic Sensitivity in Serial Pseudomonas aeruginosa Isolates from Cystic Fibrosis Airway Cultures over 12 Months.

Authors:  Isaac Martin; Dervla T D Kenna; Sandra Morales; Eric W F W Alton; Jane C Davies
Journal:  Microorganisms       Date:  2021-03-22

Review 6.  CFTR Modulator Therapies: Potential Impact on Airway Infections in Cystic Fibrosis.

Authors:  Francesca Saluzzo; Luca Riberi; Barbara Messore; Nicola Ivan Loré; Irene Esposito; Elisabetta Bignamini; Virginia De Rose
Journal:  Cells       Date:  2022-04-06       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.